Revision 1

Store at -20C

#15096

BCL9 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H	Endogenous	149	Rabbit	#O00512	607

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

BCL9 Antibody recognizes endogenous levels of total BCL9 protein. The antibody also cross-reacts with an unidentified protein of 21 kDa in some cell lines.

Species predicted to react based on 100% sequence homology

Bovine, Horse

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His138 of human BCL9 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

B-cell CLL/lymphoma 9 protein (BCL9) is a widely conserved adaptor protein that functions as a transcriptional co-activator in the canonical Wnt signaling pathway (1,2). BCL9 is a core component of a nuclear protein complex (BCL9, LEF/TCF, β-catenin and PYGO) that regulates the transcription of Wnt-dependent target genes (3). Research studies show that disrupting the interaction between BCL9 and β-catenin suppresses oncogenic Wnt signaling, suggesting a potential avenue for therapeutic intervention in Wnt-mediated cancers (4). BCL9 promotes association of PYGO with the tail of histone H3 that has been methylated at lysine 4 (H3K4me), suggesting a specific chromatin remodeling function for BCL9 in the Wnt signaling pathway (5). Research studies in colon epithelium and adenocarcinomas suggest that BCL9 is required to mediate Wnt-dependent stem cell behaviors, such as epithelial-mesenchymal transition (6). Crystallography studies revealed that BCL9 contains a β-catenin binding site that is distinct from the majority of known β-catenin binding partners, making it an attractive target for therapeutic drug development (7).

Background References

1. Townsley, F.M. et al. (2004) *Nat Cell Biol* 6, 626-33.
2. de la Roche, M. et al. (2008) *BMC Cancer* 8, 199.
3. Katoh, M. and Katoh, M. (2007) *Clin Cancer Res* 13, 4042-5.
4. Takada, K. et al. (2012) *Sci Transl Med* 4, 148ra117.
5. Fiedler, M. et al. (2008) *Mol Cell* 30, 507-18.
6. Deka, J. et al. (2010) *Cancer Res* 70, 6619-28.
7. Sampietro, J. et al. (2006) *Mol Cell* 24, 293-300.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.